PDCD1 and vitiligo: However, pneumonitis (OR 6.4, 95 % CI 3.2–12.7), hypothyroidism (OR 4.3, 95 % CI 2.9–6.3), arthralgia (OR 3.5, 95 % CI 2.6–4.8) and vitiligo (OR 3.5, 95 % CI 2.3–5.3) were more frequently observed with PD-1 inhibitors.